Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 110

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 110
---
 such capital raises may or may not be similar to transactions in which we have engaged in the past. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.

33

Cash Flows 

Cash flows are comprised of the following (dollars in thousands):Six Months Ended June 30,Change20252024AmountNet cash provided by (used in): Operating activities $89,134 $74,025 $15,109 Investing activities 6,710 (100,218)106,928 Financing activities (20,464)3,228 (23,692)Net change in cash and cash equivalents75,380 (22,965)98,345 Cash and cash equivalents at beginning of year69,331 75,054 (5,723)Cash and cash equivalents at end of period$144,711 $52,089 $92,622 

Operating Activities

Net cash provided by operating activities was $89.1 million and $74.0 million for the six months ended June 30, 2025, and 2024, respectively. The increase in cash flows provided by operating activities is primarily due to changes in working capital which reflects the timing impacts of cash collections on receivables and settlement of payables, offset by lower net income adjusted for non-cash charges for the  six months ended June 30, 2025 compared to the same period in prior year.

Investing Activities

Net cash provided by investing activities was $6.7 million for the six months ended June 30, 2025 compared to $100.2 million cash used in investing activities during the same period in 2024. The change was primarily due to lower cash outflows from purchases of marketable securities as well as higher cash inflows from the maturities of marketable securities.

Financing Activities

Net cash used in financing activities was $20.5 million for the six months ended June 30, 2025 compared to $3.2 million provided by during the same period in 2024. The change was primarily due to the payment of USWM contingent consideration milestones associated with the FDA approval and commercial launch of ONAPGO.

Material Cash Requirements

Refer to "Part II, Item 7 — Management's Discussion and Analysis of Liquidity and Capital Resources" of our Annual Report on Form 10-K for the year ended December 31, 2024, and